As people with diabetes are considered a high-risk population in the coronavirus disease 2019 (COVID-19) pandemic scenario, they are globally prioritized in COVID-19 vaccine policy. To date, in most industrialized countries, people with diabetes have already been offered the opportunity to receive a vaccine. Nonetheless, concerns exist about vaccine-induced dysglycemia among people living with diabetes, potentially holding them back from getting vaccinated. Immune responses can trigger alterations in insulin sensitivity, potentially increasing insulin requirements due to inflammation, humoral, and cellular immune responses (1). Assuming that natural immunization (infection) triggers (patho)physiological patterns similar to those of pharmacological immunization (vaccination), one can speculate that diabetes management also deteriorates after the vaccination (2), as proinflammatory cytokines increase insulin resistance (3).
Patiëntvoorbeelden m.b.t. vergoeding
- ten laste van verzekeraar
- geen vergoeding door verzekeraar